EyePoint's Second Pivotal Wet AMD Trial, LUCIA, Misses Primary Endpoint
EYPT is trading near its 52-week low of $2.93 (2.0% above the low).
Summary
EyePoint's LUCIA trial missed its primary endpoint, marking the second straight Phase 3 wet AMD failure for DURAVYU. The company now leans entirely on the DME program, whose pivotal data are not due until Q4 2027.
Key Events · Product Development and Regulatory · EYPT
-
LUCIA Misses Primary Endpoint
DURAVYU showed +2.5 letters of BCVA improvement versus +6.1 for aflibercept, a -3.7 letter difference that falls outside the -4.5 letter non-inferiority margin. The trial enrolled 475 patients.
-
Secondary Endpoints Met
Injections fell 38% (5.3 vs 3.3, nominal p<0.0001), 52% of eyes were supplement-free through Week 56, and 71% received zero or one supplement. Safety was favorable with redosing and no DURAVYU-related discontinuations.
-
Second Straight Wet AMD Failure
This follows the LUGANO miss disclosed 2026-08-17. Pooled data show 40% fewer injections and a +10 micron CST difference (nominal p=0.0064), but neither trial met the visual-acuity bar required for approval.
-
Pivot to DME Program
Management is focused on the Phase 3 COMO and CAPRI DME trials, fully enrolled in July 2026, with topline data expected in Q4 2027. Additional LUCIA and pooled analyses are ongoing to assess wet AMD next steps.
Analysis · EYPT · Industrial Applications And Services
With LUCIA, the second of two identical Phase 3 wet AMD trials has now failed its primary visual-acuity endpoint, following LUGANO in August. DURAVYU delivered +2.5 letters versus +6.1 for aflibercept — a 3.7-letter gap that falls outside the 4.5-letter non-inferiority margin — leaving the every-six-month wet AMD program with no path to an NDA on its own data. The secondary results are real: 38% fewer injections, 52% of eyes supplement-free at Week 56, and clean safety with redosing. They do not, however, rescue a failed primary endpoint. Management is pivoting the story to DME, where the Phase 2 VERONA data were positive and the Phase 3 COMO/CAPRI readout is not expected until Q4 2027. That leaves the equity valued almost entirely on a DME program with more than a year of binary risk ahead and a cash burn that produced a $94.5M quarterly loss in Q2. The stock is already near its 52-week low of $2.93, and this removes the nearer-term wet AMD catalyst.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EYPT was trading at $2.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $257.8M. The 52-week trading range was $2.93 to $19.11. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.